ALX Oncology (ALXO)

• Market cap: $213M
• 1 day: -3.66%
• 5 days: -7.6%
• 1 month: -17.28%
• 3 months: 0.64%
• 6 months: -0.63%
• Year to date: 37.39%
• 1 year: 209.8%
• 5 years: -97.8%
• 10 years: -94.73%
• Sector: Healthcare
• Industry: Biotechnology

About: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Employees: 43